Sfoglia per AUTORE
PRONZATO P
Collezione ASL Città di Torino

  

Items : 11

Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study. in Cancers / Cancers (Basel). 2023 Dec 25;16(1):117. doi: 10.3390/cancers16010117.

2023
AOU Città della Salute di Torino
ASL Città di Torino

Mustacchi G; Zambelli A; Verusio C; Turletti A; Tonini G; Tagliaferri P; Tinari N; Sarobba G; Spazzapan S; Romagnoli E; Ricciardi G; Riccardi F; Putzu C; Montemurro F; Michelotti A; Mattioli R; Marchetti P; Livi L; Latini L; Giovanardi F; Giotta F; Garrone O; Gennari A; Giordano M; Gamucci T; Forcignanò R; Ferraù F; Foladore S; Crinò L; et alii...

Triple negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study in Cancer Research

2020
ASL Città di Torino

Cazzaniga ME; Pronzato P; Arpino G; D'Alonzo A; Riemma M; Natoli C; Milani A; Blasi L; Turletti A; Giordano M; Biganzoli L; Garrone O; Diodati L; Riccardi F; Marchetti P; Bernardo A; Livi L; Fabi A; Beano A; Mustacchi G;

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies in Breast Care

2020
ASL Città di Torino

Pronzato P; Mustacchi G; Torri V; Marchetti P; Romagnoli E; Riccardi F; Natoli C; Montemurro F; Livi L; Bisagni G; Del Mastro L; Biganzoli L; Giordano M; Donadio M; Clivio L; Scavelli C; Frassoldati A; Ferzi A; Palumbo R; Gebbia V; Schirone A; Fabi A; Santini D; Porpiglia M; Turletti A; De Laurentiis M; Atzori F; Artale S; Blasi L; et alii...

Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study in Journal of Clinical Oncology

2019
AOU Città della Salute di Torino
ASL Città di Torino

Cazzaniga ME; Pronzato P; Schettini F; Del Mastro L; Riemma M; Alu M; Turletti A; Giordano M; Pugliese P; De Angelis C; Garrone O; Marchetti P; Riccardi F; Bernardo A; Livi L; Fabi A; Taverniti C; De Placido S; Mustacchi G;

Changes in hormone-receptor status in luminal breast cancers between primary tumour and metastases: Results of the observational cohort GIM-13 AMBRA study in Annals of Oncology

2019
ASL Città di Torino

Mustacchi G; Romagnoli E; Cognetti F; Donadio M; Livi L; Riccardi F; Bernardo A; Marchetti P; Garrone O; Michelotti A; Biganzoli L; Giordano M; Turletti A; Blasi L; Bisagni G; Montemurro F; Natoli C; Del Mastro L; Pronzato P; Cazzaniga ME;

First-line therapy with fulvestrant (FUL) in HR+ve, HER2-ve advanced pre-treated breast cancer (ABC) patients (pts): Results from the GIM-13 AMBRA Study in Journal of Clinical Oncology

2018
AOU Città della Salute di Torino
ASL Città di Torino

Pronzato P; Mustacchi G; Giordano M; Garrone O; Del Mastro L; Natoli C; Turletti A; Romagnoli E; Bologna A; Mocerino C; Alù M; De Angelis C; Aversa C; Arpino G; Taverniti C; Biganzoli L; Meattini I; Piezzo M; Cazzaniga ME;

Nab-paclitaxel (Nab-P) in patients (pts) with HER2-ve advanced breast cancer (ABC): A focus on the elderly- Preliminary results of the GIM-13 AMBRA study in Journal of Clinical Oncology

2018
AOU Città della Salute di Torino
ASL Città di Torino

Mustacchi G; Pronzato P; D'Alonzo A; Mocerino C; Romagnoli E; Garrone O; Blasi L; De Laurentiis M; Michelotti A; Bologna A; Giordano M; Turletti A; Montemurro F; De Placido S; Natoli C; Taverniti C; Biganzoli L; Meattini I; Marchetti P; Cazzaniga ME;

Validation of time to treatment change (TTC) as a surrogate end-point of progression free survival (PFS) for observational trials in metastatic breast cancer patients (MBC): The GIM-13 AMBRA study in Journal of Clinical Oncology

2018
ASL Città di Torino

Mustacchi G; Piezzo M; D'Alonzo A; Mocerino C; Romagnoli E; Garrone O; Blasi L; Diodati L; Bologna A; Giordano M; Bordin E; Aversa C; De Placido S; Natoli C; Taverniti C; Biganzoli L; Meattini I; Pronzato P; Cazzaniga ME;

The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study in Journal of Clinical Oncology

2017
ASL Città di Torino

Mustacchi G; Cazzaniga ME; Romagnoli E; Montemurro F; De Laurentiis M; Riccardi F; Turletti A; Beano A; De Angelis C; Graziano V; Livi L; Del Mastro L; Biganzoli L; Garrone O; De Placido S; Marchetti P; Pronzato P;

Choice of treatment and adherence to international ESO-ESMO (ABC) guidelines in HR+/HER2-ve metastatic breast cancer (MBC) patients (pts) in Journal of Clinical Oncology

2017
ASL Città di Torino

Cazzaniga ME; Mustacchi G; Romagnoli E; Montemurro F; Caporello P; De Laurentiis M; Riccardi F; Turletti A; De Angelis C; Graziano V; Livi L; Del Mastro L; Beano A; Garrone O; Biganzoli L; Pronzato P; De Placido S;

Characteristics of disease activity able to identify risk categories and probability to respond to first-line endocrine therapy (ET) in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts): Dream or reality? Evaluation of a composite risk score in a subgroup population of the GIM 13-AMBRA study in Journal of Clinical Oncology

2017
ASL Città di Torino

Mustacchi G; Cazzaniga ME; Giordano M; Garrone O; Beano A; Del Mastro L; Livi L; Iezzi L; Michelotti A; Turletti A; Riccardi F; De Laurentiis M; Marchetti P; Biganzoli L; Montemurro F; Romagnoli E; De Placido S; Pronzato P;